Elevated CA 15.3 in Newly Diagnosed Breast Cancer: A Retrospective Study.

[1]  P. Neven,et al.  Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3 , 2021, ESMO open.

[2]  P. Neven,et al.  Behavior of metastatic breast cancer according to subtype , 2020, Breast Cancer Research and Treatment.

[3]  M. Duffy,et al.  Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[4]  Weidong Wei,et al.  Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients , 2018, Disease markers.

[5]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[6]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Hortobagyi,et al.  Promoting quality and evidence-based care in early-stage breast cancer follow-up. , 2014, Journal of the National Cancer Institute.

[8]  P. Neven,et al.  The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. , 2013, Breast.

[9]  Thomas J. Smith,et al.  Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Luini,et al.  Prognostic role of CA15.3 in 7942 patients with operable breast cancer , 2012, Breast Cancer Research and Treatment.

[11]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Denis Evoy,et al.  CA 15-3: uses and limitation as a biomarker for breast cancer. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[13]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[14]  S. Gendler,et al.  Structure and function of the cell surface (tethered) mucins. , 2008, Annual review of physiology.

[15]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Peterse,et al.  The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma , 2007, Histopathology.

[17]  K. Holli,et al.  Follow-up Cost of Breast Cancer Patients with Localized Disease After Primary Treatment: a Randomized Trial , 2005, Breast Cancer Research and Treatment.

[18]  B. Reiser,et al.  Estimation of the Youden Index and its Associated Cutoff Point , 2005, Biometrical journal. Biometrische Zeitschrift.

[19]  M. Johnston,et al.  Baseline staging tests in primary breast cancer: a practice guideline. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[20]  G. Lyman,et al.  Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer , 1998, Annals of Surgical Oncology.

[21]  Y. Jung,et al.  The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry , 2019, Breast Cancer Research and Treatment.

[22]  Yan Xu,et al.  Serum CA153 as biomarker for cancer and noncancer diseases. , 2019, Progress in molecular biology and translational science.

[23]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.